BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Trichostatin A
,
rs7903146
,
DNMT1
,
T cell receptor signaling pathway
,
Obesity
,
Heart
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Tyro3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Cingulate cortex
Superior cervical ganglion
Globus pallidus
Cerebellum peduncles
Pons
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthri…
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis…
Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites.
TAM Receptors Are Not Required for Zika Virus Infection in Mice.
The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Char…
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Par…
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcin…
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carc…
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ